The U.S. Food and Drug Administration (FDA) has approved label updates for two Bristol Myers Squibb (BMS) CAR T-cell therapies, both for the treatment…
News
The U.S. Food and Drug Administration (FDA) has agreed to review an application for oral Inqovi (decitabine and cedazuridine) in combination with oral venetoclax for…
Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with KRAS G12 mutations, has been…
July 16 marks Glioblastoma Awareness Day (GBM Day), an annual observance dedicated to raising awareness about the rare and aggressive form of brain cancer, promoting…
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian cancer has begun dosing participants…
Linvoseltamab, now branded as Lynozyfic, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for treating adults with relapsed or refractory…
Senti Biosciences‘ experimental cell therapy SENTI-202 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential therapy…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GLIX1, a cancer treatment now in the preclinical stages of development, as…
The first patient has been dosed in a Phase 3 trial testing the investigational therapy BAT8006 in people with platinum-resistant ovarian cancer, according to the…
A European Medicines Agency committee has recommended that Sarclisa (isatuximab), used in combination with standard-of-care medications, be approved for the treatment of adults newly…
